Events2Join

Ventus Therapeutics CEO Marcelo Bigal


Marcelo Bigal, M.D., Ph.D. - Ventus Therapeutics

Marcelo Bigal, M.D., Ph.D. Marcelo is the President and CEO of Ventus Therapeutics, and has extensive experience in neurology. He has published over 330 peer- ...

Leadership - Ventus Therapeutics

Leadership ; Marcelo Bigal, M.D., Ph.D. · President and Chief Executive Officer ; Michele D. Bronson, Ph.D. · Chief Development Officer ; Michael Crackower, Ph.D.

Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics

Our CEO, Dr. Marcelo Bigal, joins host Matt Harbert on the latest episode of The Executive Podcast. Listen here for their discussion on ...

Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics

Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics, a company that expects to become the leader in the field of using precision ...

Ventus Therapeutics CEO Marcelo Bigal: Always Put Patients First

Ventus Therapeutics' innovative tech platform, ReSOLVE, is transforming drug discovery. Learn about their patient-centered approach and biotech ...

Leadership - Ventus Therapeutics

Leadership ; Marcelo Bigal, MD, PhD. President and Chief Executive Officer ; Michele D. Bronson, PhD. Chief Development Officer ; Michael Crackower, PhD. Chief ...

Marcelo Bigal, MD, PhD: VENT-03's Modality Offers Hope for ...

I'm the CEO and president of Ventus Therapeutics, and I have some experience in developing medications. Related Content ...

Ventus Therapeutics CEO Marcelo Bigal: Always Put Patients First

we know exactly who we serve. We don't serve the target, we don't serve the protein, we don't serve the platform. We serve the patients who ...

Board of Directors - Ventus Therapeutics

Dolca Thomas, M.D.. Venture Partner, Samsara BioCapital ; Markus Warmuth, M.D.. Chief Executive Officer, Monte Rosa Therapeutics ; Marcelo Bigal, M.D., Ph.D.

Marcelo Bigal - President and CEO @ Ventus Therapeutics

Marcelo Bigal is the President and CEO of Ventus Therapeutics. He attended New England Center for Headache.

Ventus Therapeutics | SoftBank Group Corp.

Marcelo Bigal CEO ... Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying leading-edge technologies to discover new drug candidates, which ...

Marcelo Bigal Coverage - MedCity News

RA Capital led Ventus Therapeutics' Series B financing, which the startup will use to develop its pipeline of medicines for “undruggable” disease targets. CEO ...

Ventus Therapeutics to Present at the Stifel 2023 Healthcare ...

Ventus Therapeutics announced today that its President and Chief Executive Officer Marcelo Bigal, M.D., Ph.D., will present at the Stifel ...

Innate Immunity and Elusive Targets - Ventus Therapeutics

Marcelo Bigal, MD, PhD, President and CEO of Ventus Therapeutics and Judith Lieberman, MD, PhD, Professor of Pediatrics, Harvard Medical School.

Marcelo Bigal - The 10th Piper Sandler Heartland Summit

Marcelo Bigal. CEO, Ventus Therapeutics. Ventus Therapeutics is a U.S.-based company with a subsidiary in Montreal, CA (www.ventustx.com). Bigal joined Ventus ...

Ventus Therapeutics - Portfolio - SoftBank Vision Fund

Ventus Therapeutics is using computational tools to unlock elusive drug targets that address human disease. Leadership. Marcelo Bigal.

Marcelo Bigal Ph.D Profile: Contact Information & Network - PitchBook

Marcelo Bigal Ph.D General Information. Biography. Dr. Marcelo Bigal serves as Chief Executive Officer and President at Ventus Therapeutics.

Broadening the Scope of Small Molecules: Ventus Therapeutics

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule ...

Marcelo Bigal Email & Phone Number | Ventus Therapeutics ...

Marcelo Bigal's Work. 2019 - now President and CEO @ Ventus Therapeutics; 2019 - 2022 Board Member - Coda Biotherapeutics @ CODA Biotherapeutics ...

Ventus Therapeutics Appoints Three New Members to Board of ...

... Marcelo Bigal, MD, PhD, president and CEO of Ventus. “Jane is a veteran biopharmaceutical executive, a multiple-time CFO with significant ...